Biotechnology News and Research

RSS

Bavarian Nordic to file a NDS for IMVAMUNE with Health Canada

Bavarian Nordic A/S announced today that the company expects to file a New Drug Submission (NDS) for its third-generation smallpox vaccine, IMVAMUNE(R) with the Canadian Authorities, Health Canada in 2010. If successful, this would be the first marketing approval of IMVAMUNE(R).

30 Nov 2009

Spectrum Pharmaceuticals completes enrollment in apaziquone Phase 3 trial

Spectrum Pharmaceuticals today announced that one of the two Phase 3 pivotal clinical trials of apaziquone has achieved its enrollment target, having enrolled approximately 800 patients with non-invasive bladder cancer. The second Phase 3 clinical trial of apaziquone is expected to complete enrollment by the end of the year.

30 Nov 2009

$Stem cell technology for rapid healing of complicated bone fractures$

Stem cell technology for rapid healing of complicated bone fractures

A novel technology involving use of stem cells, developed by Hebrew University of Jerusalem researchers, has been applied to provide better and rapid healing for patients suffering from complicated bone fractures.

30 Nov 2009

WuXi PharmaTech recognized as 50 fastest-growing companies for the fifth consecutive year

WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology, and medical-device research and development outsourcing company with operations in China and the United States, announced that it had been selected to the Deloitte Technology Fast 50 China 2009 list for the fifth consecutive year.

30 Nov 2009

Intellivest Securities Research publishes a Report on BioClinica

Intellivest Securities Research, Inc., ("ISR") a Georgia registered investment advisor, has published a Report on BioClinica, Inc. ( BIOC) which serves companies in the pharmaceutical, biotechnology and medical device industries.

30 Nov 2009

XenaCare Holdings becomes national sponsor of Arthritis Foundation

XenaCare Holdings, Inc., a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that is has become a national sponsor of the Arthritis Foundation at the National Proud Sponsor level.

27 Nov 2009

Kane Biotech increases current private placement offering from 3,846,154 units to 4,335,500 units

Kane Biotech Inc., a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms, today announces that it has increased the current private placement offering (the "Offering"), first reported on November 16, 2009, from a maximum of 3,846,154 units to 4,335,500 Units, for total gross proceeds of up to $563,615.

27 Nov 2009

Cannasat Therapeutics reports net loss of $336,154 for the three months ended September 30, 2009

Cannasat Therapeutics Inc., a clinical stage pharmaceutical company developing products to treat neurological disorders, today announced its results for the nine months ended September 30, 2009. Unless specified otherwise, all amounts are in Canadian dollars.

27 Nov 2009

NCKU, ScinoPharm Taiwan sign MOU to establish university-industry cooperation

National Cheng Kung University (NCKU), Taiwan signed a MOU with ScinoPharm Taiwan Ltd. on Nov. 24th.

27 Nov 2009

International collaborative research projects to decipher the biology behind the ageing process

Research efforts to help the world's ageing population live longer healthier lives have been given a major boost with the announcement of six new transatlantic research projects aiming to understanding the biology of the ageing process.

26 Nov 2009

AMPAC Fine Chemicals receives Environmental Responsibility and Sustainability Award

AMPAC Fine Chemicals LLC (AFC), a subsidiary of American Pacific Corporation (Nasdaq: APFC) announced today that it received the Environmental Responsibility and Sustainability Award at the Annual Statewide Environmental Summit, sponsored by the California Manufacturers and Technology Association (CMTA), the Industrial Environmental Association (IEA) and the Chemical Industry Council of California (CICC) held in San Diego.

26 Nov 2009

Expanded HIV vaccine funding for biotechnology research crucial, says TAI

In honor of World AIDS Day, The AIDS Institute (TAI), one of the nation's leading advocacy organizations for support of people with HIV/AIDS and their providers, joined Nobel Laureate Dr. Francoise Barre-Sinoussi, in calling for government leaders, patient advocates and the research community to expand therapeutic HIV vaccine research.

26 Nov 2009

Scientists offer first genetic proof of new and rational treatment for osteoporosis

The so-called RANK protein and the molecule that binds to it, the RANK ligand or RANKL, form a focus of the work of Josef Penninger, director of the Institute of Molecular Biotechnology (IMBA) in Vienna. In 1999 his group deleted the RANKL gene from mice and showed that the RANK/RANKL system was the "master regulator" governing bone loss (Kong et al. 1999 Nature 402, 304-309).

26 Nov 2009

Lethality of H1N1 virus has dropped from its peak of 3.7, shows new data

Biotech firm Replikins Ltd., which has analyzed the H1N1 virus' genomic data from the 1918 pandemic through the prediction, outbreak, and progress of the current H1N1 pandemic, today issued its latest biochemical analysis of the virus.

25 Nov 2009

Simulations Plus launches new version of GastroPlus

Simulations Plus, Inc., a leading provider of simulation and modeling software for pharmaceutical discovery and development, announces the release of GastroPlus Version 6.1, the latest version of its state-of-the-art software used by pharmaceutical research scientists for simulation of oral absorption, intravenous dosing, pharmacokinetics, and pharmacodynamics.

25 Nov 2009

iThemba Pharmaceuticals and Pyxis Discovery sign a collaborative agreement

iThemba Pharmaceuticals' service division and Pyxis Discovery announced today that they have signed a collaborative agreement to jointly market both companies' services.

25 Nov 2009

Illumina's Board of Directors authorize a new stock repurchase program

Illumina, Inc. today announced that its Board of Directors has approved a new stock repurchase program, authorizing the company to repurchase in the aggregate up to $100 million of its outstanding common stock. The $75 million share repurchase program originally announced on August 24, 2009, recently has been completed.

From Illumina, Inc. 25 Nov 2009

Vicor Technologies announces implementation of ASP distribution model in cardiology practice

David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced the beta test installation of the company's application service provider (ASP) distribution model in a U.S. cardiology practice.

25 Nov 2009

Tennessee Biotechnology Association to host workshop on biotechnology industry

The Tennessee Biotechnology Association and its Graduate Alliance are jointly hosting an afternoon of biotech, business, and law on December 7th, 2009. This event will be held at Belmont University with a reception at 5pm sponsored by i3 Research.

25 Nov 2009

Positive Phase II/III clinical data from ChemoCentryx' PROTECT-1 Traficet-EN trial

ChemoCentryx, Inc., announced today that Phase II/III clinical data from the Company's PROTECT-1 (the Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial) of Traficet-EN(TM) (CCX282-B) in patients with moderate-to-severe Crohn's disease demonstrated clinical efficacy with a favorable safety and tolerability profile. The

25 Nov 2009

Biotechnology News and Research

Bavarian Nordic to file a NDS for IMVAMUNE with Health Canada

Spectrum Pharmaceuticals completes enrollment in apaziquone Phase 3 trial

Stem cell technology for rapid healing of complicated bone fractures

WuXi PharmaTech recognized as 50 fastest-growing companies for the fifth consecutive year

Intellivest Securities Research publishes a Report on BioClinica

XenaCare Holdings becomes national sponsor of Arthritis Foundation

Kane Biotech increases current private placement offering from 3,846,154 units to 4,335,500 units

Cannasat Therapeutics reports net loss of $336,154 for the three months ended September 30, 2009

NCKU, ScinoPharm Taiwan sign MOU to establish university-industry cooperation

International collaborative research projects to decipher the biology behind the ageing process

AMPAC Fine Chemicals receives Environmental Responsibility and Sustainability Award

Expanded HIV vaccine funding for biotechnology research crucial, says TAI

Scientists offer first genetic proof of new and rational treatment for osteoporosis

Lethality of H1N1 virus has dropped from its peak of 3.7, shows new data

Simulations Plus launches new version of GastroPlus

iThemba Pharmaceuticals and Pyxis Discovery sign a collaborative agreement

Illumina's Board of Directors authorize a new stock repurchase program

Vicor Technologies announces implementation of ASP distribution model in cardiology practice

Tennessee Biotechnology Association to host workshop on biotechnology industry

Positive Phase II/III clinical data from ChemoCentryx' PROTECT-1 Traficet-EN trial

Biotechnology eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News